Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Non-Current Assets (2016 - 2025)

Neurocrine Biosciences' Other Non-Current Assets history spans 16 years, with the latest figure at $59.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 14.42% year-over-year to $59.5 million; the TTM value through Dec 2025 reached $59.5 million, up 14.42%, while the annual FY2025 figure was $59.5 million, 14.42% up from the prior year.
  • Other Non-Current Assets reached $59.5 million in Q4 2025 per NBIX's latest filing, up from $20.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $61.6 million in Q3 2024 to a low of $1.4 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $28.0 million, with a median of $23.2 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 621.43% in 2022, then tumbled 69.94% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $4.4 million in 2021, then surged by 468.18% to $25.0 million in 2022, then soared by 98.4% to $49.6 million in 2023, then increased by 4.84% to $52.0 million in 2024, then grew by 14.42% to $59.5 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Non-Current Assets are $59.5 million (Q4 2025), $20.3 million (Q3 2025), and $21.6 million (Q2 2025).